Video

Dr. Master on the Mediterranean Diet in Relation to Breast Cancer Risk

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.

The Mediterranean diet is high in fruits, vegetables, whole grains, animal proteins sourced mainly from fish, and good fats derived from nuts. The diet is low in red meat and processed meats, which are components of a typical Western diet, says Master. Data have suggested that women who follow a Mediterranean diet have a decreased risk of developing breast cancer.

Another component of breast cancer risk is physical activity, says Master. Even in women who are not overweight, data have shown that physical activity is still beneficial. Although, it is especially important to incorporate physical activity, in addition to diet, into a treatment plan for overweight and obese women at risk for breast cancer.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD